Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates

Guangdong Women and Children Hospital

Status: Enrolling

Conditions: Neonatal Disease

Treatments: Other: Whole-proteomic assay

Study type: Observational

Funder types: Other

Identifiers

NCT06206590

202301393

Details and patient eligibility

About

1. Explore 32 weeks of premature infants or maternal pregnancy infection of newborn septic shock maternal influence factors. 2. Through maternal blood samples before delivery and labor cord blood sample screening and septic shock related proteomics analysis, explore the relationship between the difference protein and septic shock and prognosis, and explore the pathway mechanism, in order to prevent and reduce the occurrence of septic shock in premature infants

Full description

The birth cohort was established with 32 weeks of premature infants or maternal infection during pregnancy.Whole proteomic analysis was performed on maternal blood before delivery and umbilical cord blood samples at delivery,and screscreen differential proteins associated with septic shock and classify these proteins as leak factor into exposed and non-exposed groups for cohort study.The incidence and mortality of shock,severe brain injury and BPD in the two groups were compared, and the mechanism of the differential protein was studied to provide early warning in children with septic shock.

Enrollment: 116 estimated patients

Sex: All

Ages: 1 to 1 day old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All ≤32-week premature infants admitted to our NICU; All newborns delivered by the mother infected during pregnancy

Exclusion criteria

• Not delivered in our hospital; congenital cardiovascular development malformation, fetal malformation, genetic metabolic diseases, etc

Trial design

116 participants in 2 patient groups

exposed group

Description:

Contains differential proteins

Treatment:

Other: Whole-proteomic assay

non-exposed group

Description:

No differential protein

Treatment:

Other: Whole-proteomic assay